I don't recall the exact numbers, but BMRA posted disappointing earnings this last quarter. In each quarter prior to that for quite sometime now, earnings have been up dramatically, but would have been higher: the fault has been on Lancer subsidiary, always with the notation that things have improved there and should add to earnings in the next quarter. Same this time. Yet they persist in believing in it, and I'm not suggesting they sell it, but I wonder what the hold-up is in turning it around? I've not been clear on this. I haven't seen Lancer's price today, but in general terms its been up recently. (There was a reverse split in that stock, 7 to 1 as I recall, it weakened briefly then went up a little).
Anyway, I don't think BMRA has been manipulated much, if any, over the last nine months or so. But I do think there was some or alot of this before that time. I have no proof of this, just owned it for five years and have watched it almost daily. I believe that it is underhyped, and that's okay with me. Until I have the number of shares I want to be holding when it starts paying dividends. However, the earnings alone would not support it at this price. But those products in the pipeline for approval sound really, really good. Next year, the earnings will begin rolling in. I'm not certain what the prospects of earnings going up much this quarter are, but they are much much better at marketing now, having been a research and research and research some more company for many years, even after having product to sell. As someone with allergies, I hope their allergy solution works really well. The earnings for those of us with shares of stock will also be nice.
Just my thoughts on the company.
Regards,
Ron |
